HIKAL LTD. - 524735 - Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Announcement under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201523-02-2024
23-02-2024
HIKAL LTD. - 524735 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcement under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Newspaper Publication20-02-2024
HIKAL LTD. - 524735 - Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Announcement under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201519-02-2024
HIKAL LTD. - 524735 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Notice of Postal Ballot pursuant to the provision of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201519-02-2024
HIKAL LTD. - 524735 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcement under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations , 2015 - Earnings call Transcript15-02-2024
HIKAL LTD. - 524735 - Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Announcement under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201513-02-2024
Q3FY24 Quarterly Result Announced for Hikal Ltd.
Pharmaceuticals company Hikal announced Q3FY24 results: Financial Highlights Revenue: Revenue for the quarter was reported at Rs 448 crore, marking a sequential growth of 3% from the previous quarter. EBITDA: Earnings before interest, tax, depreciation, and amortization (EBITDA) stood at Rs 65 crore. This represents a 13% increase on a quarter-over-quarter basis. PAT: Profit after tax (PAT) reached Rs 16 crore for the quarter, showing a significant increase of 32% from the second quarter. Interim Dividend: The company declared an interim dividend of Rs 0.60 per share, which constitutes 30% of the face value. Business Segment Performance Pharmaceutical Division: Pharmaceutical sales were reported at Rs 267 crore, contributing significantly to the quarter's revenue. Crop Protection Division: Crop Protection saw revenues of Rs 180 crore for this quarter. Operational Highlights Margins: Improvements in margins were attributed to the softening of raw material prices and the implementation of business excellence initiatives. Industry Destocking: The Crop Protection Industry experienced continued destocking, impacting the overall demand dynamics. Global Exposure: The company reported notable traction for its newer pharmaceutical product portfolio in geographies such as Japan, Latin America, and the Middle East. New Facilities: A new multipurpose Animal Health Plant at Panoli has been successfully commissioned during this quarter. Commenting on the results, Jai Hiremath, Executive Chairman, Hikal said, “The global chemical industry continues to witness turbulence on the back of increased inventory levels, higher interest rates and intense price competition. We see prices bottoming out over the next few months and at the same time we can see things improving in the industry going forward. For Q3FY24, we reported revenues of Rs 448 crore and EBITDA of Rs 65 crore. The softening of raw materials prices coupled with focused cost improvement, lean initiatives and a diversified product mix helped us to improve our margins sequentially on a QoQ basis. Our pharmaceutical business reported revenues of Rs 267 crore and EBIT of 18 crore for Q3FY24. In the API business, we are seeing traction on the back of improved penetration across different geographies, stabilized prices and signs of recovery in market demand. On the CDMO side, we continue to maintain a strong pipeline of enquiries from several Pharma innovators, and several products are in the advanced stages of development. For Q3FY24, our crop protection business reported revenue of Rs 180 crore and EBIT of 22 crore. The global crop protection industry continues to experience severe headwinds. Subdued global demand on the back of the destocking situation coupled with intense price competition has impacted the industry. Proactive implementation of cost improvement programs has benefited us this quarter in maintaining the margin profile. Our new multi-purpose facility at Panoli is completed and stabilization of the plant is in progress. Result PDF09-02-2024
HIKAL LTD. - 524735 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Submission of audio recording of earnings conference call for the period ended Q3 FY2409-02-2024
HIKAL LTD. - 524735 - Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)
Press release dated February 8, 2024 titled "Sequential recovery in Q3 FY24"09-02-2024
Hikal Q3 results: Net profit down 38% to Rs 16 crore
Hikal's revenue came in at Rs 448 crore, down 17 percent from the year-ago quarter of Rs 540 crore.08-02-2024